NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Precigen, Inc. (PGEN) Stock Analysis

Precigen, Inc. (PGEN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PGEN

$7.10

−$0.04 (−0.56%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PGEN with… →

PGEN Key Statistics

As of Sep 4, 2026
Trading
Open
$7.12
Previous Close
$7.14
Day's Range
7.08–7.27
52-Week Range
2.99–7.72
Volume
2.19M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.02
Valuation
Market Cap
$2.54B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
29.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.07
Financials (FY)
Revenue (FY)
$9.68M+146.73%
Net Income (FY)
−$250.64M
Profit marginThe share of revenue left as profit after all costs and taxes.
−183.98%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
358.04M
1-Year Return
+55.70%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
5.18M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PGEN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+69.86%
2025+273.21%
2024−16.42%
2023−11.84%
2022−59.03%
2021−63.63%
2020+86.13%
2019−16.21%
2018−43.23%
2017−52.17%
2016 (partial year)−10.17%

As of September 4, 2026.

PGEN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$9.68M−$250.64M−2588.2%
2024$3.93M−$126.24M−3216.2%
2023$6.23M−$95.90M−1540.6%
2022$26.91M$28.32M105.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.68M$4.86M−$106.60M−$250.64M−2588.2%
2024$3.93M−$342.00K−$94.71M−$126.24M−3216.2%
2023$6.23M$106.00K−$88.92M−$95.90M−1540.6%
2022$26.91M$20.57M−$74.61M$28.32M105.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PGEN Valuation vs Biotechnology Median

Median of 656 stocks
MetricPGENBiotechnology medianvs median
P/S ratio29.6615.2694% above
Profit margin−183.98%0.00%184.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Precigen, Inc. (PGEN) carries a market capitalisation of $2.54B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 160 employees.

The most recent close on file for PGEN is $7.10, dated September 4, 2026. That is −$0.04 (−0.56%) against the previous close. Over the past 52 weeks the price has ranged from $2.99 to $7.72. The latest close sits 137.46% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $9.68M. Against the prior fiscal year total of $3.93M, that is a change of +146.73%. The same year closed with a net loss of $250.64M. The reported profit margin is −183.98%. That is 184 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −1.07.

Across the 4 fiscal years on file, revenue moves from $26.91M in 2022 to $9.68M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 29.66. On price-to-sales that is 94.29% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.02. Daily returns over the trailing 10 years annualize to a volatility of 91.54%. The trailing one-year price return is +55.70%. Measured over 10 years, that is −11.86% a year compounded.

Growth & Income

The record shows no dividend for PGEN.

The strongest complete calendar year on file is 2025 at +273.21%; the weakest is 2021 at −63.63%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is +69.86%.

Peer Comparison

Precigen, Inc. (PGEN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Precigen, Inc. PGEN $2.54B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Precigen, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Precigen, Inc.

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Visit website →